ALSO NOTED: Novartis plots $700M biotech plant; Genzyme wins marketing approval; Glenmark, Forest to pursue Phase II; and much

> Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. Report

> Genzyme has won FDA marketing approval for Epicel, a therapy for severe burns. Release

> Researchers at Glenmark Pharmaceuticals and Forest Laboratories have been given a partial favorable response for an additional mid-stage study of GRC 3886 for asthma and COPD. Report

> Warburg Pincus has wrapped its $3.67 billion buyout of Bausch & Lomb. Release

> Shares of Dusa Pharmaceuticals surged this morning on the news that it had settled a patent dispute with River's Edge Pharmaceuticals regarding Nicomide. Report

> Look for a crackdown on direct-to-consumer ads if John Edwards is elected in 2008. Report

> You win some, you lose some. Bayer is abandoning plans to launch a bigger dose of its multiple sclerosis treatment Betaferon. Report

> Outgoing GlaxoSmithKline CEO Jean-Paul Garnier is shouldering the heavy load of layoffs and restructuring to give his successor Andrew Witty a clean slate when he takes over next May, the Times of London is reporting. Report

And Finally... Scientists from Bangor University have found a 400-year-old clam, the oldest living animal known to science. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.